Tratamento do melanoma cutâneo estádios III e IV

Neves, Rogério Izar; Duprat Neto, João Pedreira; Brechtbuhl, Eduard René; Castanheira, Débora; Feher, Olavo; Maia, Maria Aparecida Conte; Pizão, Paulo Eduardo.
Acta oncol. bras ; 23(2,n.esp): 462-465, 2003.
Artigo em Português | LILACS | ID: lil-432590

Documentos relacionados

  1. Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma.
  2. Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence.
  3. Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.
  4. Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.
  5. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
  6. National Trends in Management of Pathologic Stage III Melanoma.
  7. A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.
  8. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
  9. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
  10. Recent Changes and Innovations in Melanoma Treatment: A Review.